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Introduction
Revised guidelines for the management of heart failure (HF) 
were published in 2013.1 HF arises due to a reduction in 
cardiac output secondary to a reduction in stroke volume 
(SV). Systolic HF (SHF) arises due to overfilling of a dilated 
left ventricle (LV) and/or right ventricle with inadequate 
ejection, and thus a reduced ejection fraction (EF). SHF 
progressively limits activity and results in increasing back 
pressure and secondary congestion of the pulmonary and/
or systemic venous circulation.2 However, the majority 
of patients with HF have preserved or even exaggerated 
systolic function, with a normal or increased EF owing 
to diastolic heart failure (DHF). SV is reduced because 
of underfilling of a stiff LV. Sudden-onset dyspnoea in 
response to stress or exercise occurs as a result of raised 
LV end-diastolic pressure (LVEDP). Congestion owing to an 
intermittent or persistent increase in LVEDP is thus an early, 
prominent feature of diastolic dysfunction.3
Pathophysiology
Systolic heart failure
Therapy for SHF is reviewed comprehensively in the 
American Heart Association (AHA) guidelines.1 Positive 
inotropes increase metabolic demand on remaining 
myocytes, resulting in accelerated apoptosis. Mortality 
is increased when positive inotropes are used in the 
management of acute or chronic SHF.4
Systolic function can be markedly improved by cardiac 
resynchronisation therapy by means of dual chamber pacing 
and/or placement of an implantable cardioverter-defibrillator. 
These devices should be interrogated preoperatively and a 
management plan devised in conjunction with the inserting 
cardiologist.5 
Forward flow from the failing ventricle may be reliably 
improved by insertion of a ventricular assist device. Despite 
expense and morbidity, these devices are being used more 
frequently.6
Diastolic heart failure
The pathophysiology of DHF7 is markedly different from 
that of SHF. The LV in a patient with diastolic dysfunction 
is likely to be hypertrophied (because of hypertension) and 
prone to ischaemia (as a result of coronary artery disease), 
resulting in failure of relaxation (decreased lusitropy). SV is 
reduced by limitation of filling and is crucially dependent on 
preload. EF is maintained or even increased, leading to a 
possible misdiagnosis of good systolic function if diastolic 
dysfunction is not assessed.
Diagnosis of heart failure
Clinical history
A subtle feature of the clinical history8 is progressive 
dyspnoea and a reduction in the effort tolerance with SHF, 
compared with normal activity below a certain threshold 
in DHF. Assessment of effort tolerance should be made 
using the AHC/American College of Cardiology Foundation 
(ACCF) quantification of metabolic equivalents.1
Examination 
During examination,8 the presence of peripheral and 
pulmonary oedema should be assessed. Blood pressure 
(BP) is typically reduced with SHF, but normal or more 
commonly elevated in DHF. SHF results in dilation as a 
prominent feature with a diffuse apex. DHF will result in an 
undisplaced apex with a hyperdynamic quality.
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Investigation 
Basic investigations8 include:
•	 Electrocardiogram	 (ECG):	 An ECG will reveal rhythm 
abnormalities, ventricular hypertrophy, as well as an old 
infarction.
•	 Urea	 and	 electrolytes: Hyponatraemia < 130 mmol/l 
predicts poor prognosis in SHF. 
•	 Hypo- or hyperkalaemia may arise, either primarily or 
due to therapy. 
•	 An independently raised urea indicates overdiuresis. 
•	 Chest	X-ray: A chest X-ray will reveal pulmonary oedema9 
as well as other pathologies, such as pneumonia, 
tuberculosis or pericardial or pleural effusions.
Brain natriuretic peptide levels
Brain natriuretic peptide (BNP)10 and N-terminal pro-brain 
natriuretic peptide are raised in heart failure, but not in 
chronic obstructive pulmonary disease, thus differentiating 
cardiac from respiratory dyspnoea. Declining levels are a 
reassuring sign of effective therapy, whereas persistent or 
rising levels are a cause for concern.
Echocardiography
Systolic dysfunction will be easily revealed on 
echocardiography11 (ECG) by a dilated and poorly contractile 
LV. 
Diastolic dysfunction is much more difficult to diagnose 
relying on assessment of LV inflow (E/A ratio). A normal 
EF does not exclude a diagnosis of DHF, but is actually 
confirmatory.
Stress tests
A six-minute walk test may be performed in the ward. 
Distances < 200 m indicate poor prognosis, while > 300 m 
indicates good prognosis.12 
Distances of 2-300 m require further testing, such as a 
dobutamine stress ECG. A positive response to dobutamine 
improves prognosis, while failure to respond, or a response 
with ischaemia, worsens prognosis.13
Treatment of diastolic heart failure
Beta blockers
Patients who are hypertensive and who have DHF require 
beta blockers which reduce myocardial contractility, 
reducing LVEDP. A slower heart rate lengthens diastolic 
time, maximises filling and improves ejection, thus reducing 
congestion.14 Beta blockers should not be commenced in 
the immediate perioperative period because of an increased 
risk of strokes.15
Vasodilation
Initial vasodilation is best achieved with nitrates. A positive 
response to nitrates is indicative of a favourable response 
to diuretics.16 
Long-term vasodilation is best achieved with angiotensin-
converting enzyme (ACE) inhibitors or angiotensin-receptor 
blockers (ARBs).17
Labetalol is a very useful drug in the intensive care unit 
(ICU) setting, combining both alpha (vasodilation) and beta-
blocking effects.18
Diuretics
Loop diuretics are effective decongestants, particularly of 
the pulmonary circulation, mainly through their venodilator 
effects.19 Excessive use of diuretics reduces preload, SV 
and forward flow. An adverse effect on the renal function is 
seen in the cardiorenal syndrome.20 
Warning of excessive diuresis is persistently elevated 
jugular venous pressure (JVP) or central venous pressure 
(CVP), confirmed by a rising urea with a static creatinine.
Perioperative heart failure
The ACCF/AHA guidelines for assessment of cardiac 
patients for non-cardiac surgery recognises the significant 
effect of heart failure21 on postoperative mortality. 
The management strategy for DHF differs markedly to that 
for SHF in the coronary care unit and cardiac ward, so is 
also likely to differ in the operating room and ICU.
Preoperative decision-making
Stable patients with previous heart failure
Patients with a previous episode of HF who are currently 
stable on therapy should have their therapy continued 
in the perioperative period. There is some controversy 
surrounding the perioperative administration of ACE 
inhibitors and ARBs.22 Patients undergoing cardiac or major 
vascular surgery, who are likely to require inotropic and/
or vasopressor support, should have these medications 
withheld. The majority of patients should continue to use 
these agents. 
Beta blockers should not be stopped perioperatively owing 
to the risk of myocardial ischaemia.23
Patients with acute heart failure requiring surgery
Patients with acute heart failure requiring surgery24 should 
be treated as follows: 
Patients with end-stage SHF who are not candidates for 
transplant or a LV assist device may not be able to have 
surgery, and may require palliative care.25 
Patients with acute DHF may respond very rapidly to therapy. 
A period of 4-6 hours is likely to be of great benefit, using 
therapy with labetalol, with the addition of nitroglycerine, if 
tolerated. 
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Intraoperative management
Systolic dysfunction
A neuraxial block in systolic dysfunction26 results in 
vasodilation and sympathectomy that are beneficial 
to forward flow. Hypotension should be managed with 
vasopressors, rather than fluids. General anaesthetic drugs 
are cardiovascular depressants, so the lowest effective 
doses of the least depressant agents should be chosen. 
Propofol and the synthetic opioids must be avoided. Low-
dose ketamine for induction and maintenance is extremely 
useful, especially with the addition of nitrous oxide. The 
volatile agent of choice is desflurane, owing to minimal 
tissue absorption. 
Postoperative analgesia should encompass a multimodal 
approach, including local anaesthetics, paracetamol and an 
opioid (tramadol, morphine or oxycodone). Non-steroidal 
anti-inflammatory drugs (NSAIDs) should be avoided 
because of the risk of fluid overload and renal dysfunction.
Diastolic dysfunction
Neuraxial blocks are also beneficial for patients with 
diastolic dysfunction,27 as long as preload is maintained. 
General anaesthetic agents should be chosen to limit 
sympathetic activation and provide systemic and pulmonary 
vasodilation. The alpha 2 agonists are ideal baseline drugs 
for DHF. Propofol and synthetic opioids such as remi- and 
sufentanil provide titratable anaesthesia and analgesia. 
Desflurane may cause a tachycardia if the underlying 
sympathetic tone is high. Sevoflurane is neutral, while 
isoflurane provides vasodilation. All of the volatile agents 
provide myocardial protection through preconditioning. 
Postoperative analgesia is similar to that with SHF. NSAIDs 
may be used in the absence of contraindications, particularly 
renal dysfunction.
Postoperative care
The management of systolic dysfunction in the postoperative 
period is a continuation of preoperative therapy.
Patients may develop diastolic dysfunction for the first 
time in the postoperative period. The presence of basal 
crepitations, signs of pulmonary oedema on chest X-ray, 
and a normal EF on ECG, often lead to the institution of 
high-dose diuretic therapy, despite a normal or elevated BP. 
Diuretics reduce preload and thus filling of the LV, with 
worsening of ejection and persistence, or worsening of 
symptoms. JVP and CVP remain elevated, urea rises 
independent of creatinine, and BNP levels rise. 
These patients require:
•	 Cessation of diuretics.
•	 Institution of labetalol 5-10 mg stat, followed by 1-5 mg/
minute (60-300 mg/hour).
•	 The addition of nitroglycerine 5 µg/minute (300 µg/hour) 
to a maximum of 20 µg/minute (1 200 µg/hour) with 
normotension and without tachycardia.
•	 Oral therapy with a beta blocker and ACE inhibitor 
or ARB should be commenced in consultation with a 
cardiologist. 
•	 As the oral drugs take effect, the labetalol and 
nitroglycerine are weaned off.
•	 After stabilisation, the patient should be further evaluated. 
Coronary artery disease may require revascularisation. 
A statin and low-dose aspirin should be commenced, 
smoking should be stopped and advice given on diet 
and exercise.
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